Please login to the form below

Not currently logged in
Email:
Password:

pulmonary fibrosis

This page shows the latest pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.

Fishawack acquires brand communications agency Healthcircle

Fishawack acquires brand communications agency Healthcircle

Healthcircle has also worked on a variety of campaigns in the areas of oncology, idiopathic pulmonary fibrosis and consumer health to name a few.

Latest news

More from news
Approximately 7 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Ark has in-licensed the global rights to the phase 1. idiopathic pulmonary fibrosis programme. ... the phase 1 product AK3280 (GDC3280) for the treatment of idiopathic pulmonary fibrosis.

  • 30 Women Leaders in UK Healthcare (part 3) 30 Women Leaders in UK Healthcare (part 3)

    2004. Fifteen years on, the company’s lead product candidate, Lynovex, for the treatment of acute pulmonary exacerbations in Cystic Fibrosis, was recently granted FDA Fast Track Designation.

  • Getting multichannel marketing right Getting multichannel marketing right

    In recent years, Merck has run an animated video to raise awareness of thyroid disorders, Roche has recorded a choir made up of families affected by idiopathic pulmonary fibrosis and AstraZeneca

  • Significant figures Significant figures

    NTM is a rare progressive, destructive infection that’s normally found in addition to pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or bronchiectasis. ... Its novel therapy is an inhaled formulation of

  • Deal Watch June 2016 Deal Watch June 2016

    pulmonary fibrosis (IPF) with cough. ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219, oral P2X3 antagonist for chronic cough (p2b) and idiopathic pulmonary fibrosis (p2) with cough, and other compounds.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Innovation and technology at Roche’s “Air Spain” Event

    The event Air Spain organised by Roche, spoke about how to  optimise research, knowledge and treatment of idiopathic pulmonary fibrosis.

  • Understanding the "Big Picture"

    For example, a technology originally intended to monitor the presence of lung fibrosis in idiopathic pulmonary fibrosis (IPF) but then finding utility in other fibrotic lung diseases. ... Keeping with the example of fibrosis, if the targets are viable,

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics